Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate
C Edoardo, C Giuseppe - Expert Opinion on Investigational Drugs, 2024 - Taylor & Francis
ABSTRACT Introduction Antibody–drug conjugates (ADCs) represent a revolutionary
approach in the systemic treatment for both solid and hematologic tumors. Constituted by an …
approach in the systemic treatment for both solid and hematologic tumors. Constituted by an …
[HTML][HTML] Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis
F Schettini, S Nucera, T Pascual… - Cancer Treatment …, 2024 - Elsevier
Abstract Introduction Antibody-drug conjugates (ADCs) trastuzumab-deruxtecan (T-DXd)
and sacituzumab-govitecan (SG) provided significant progression-free survival (PFS) and …
and sacituzumab-govitecan (SG) provided significant progression-free survival (PFS) and …
Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer
Z Yi, K Feng, D Lv, Y Guan, Y Shao, F Ma… - Signal Transduction and …, 2024 - nature.com
The large population of HER2-low breast cancer patients necessitates further research to
provide enhanced clinical guidance. In this study, we retrospectively analyzed 1071 …
provide enhanced clinical guidance. In this study, we retrospectively analyzed 1071 …
A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression
C Boman, X Liu, L Eriksson Bergman, W Sun… - British Journal of …, 2024 - nature.com
Background This study aimed to investigate the distribution and changes of HER2 status in
untreated tumours, in residual disease and in metastasis, and their long-term prognostic …
untreated tumours, in residual disease and in metastasis, and their long-term prognostic …
Comprehensive assessment of immune phenotype and its effects on survival outcomes in HER2-low versus HER2-zero breast cancer
Background The understanding of molecular characteristics of HER2-low breast cancer is
evolving since the establishment of trastuzumab deruxtecan. Here, we explore the …
evolving since the establishment of trastuzumab deruxtecan. Here, we explore the …
Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort …
F Schettini, E Blondeaux, C Molinelli, R Bas, HJ Kim… - Cancer, 2024 - Wiley Online Library
Background Breast cancer (BC) in women aged≤ 40 years carrying germline pathogenetic
variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features …
variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features …
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13 …
G Nader-Marta, C Singer, D Hlauschek… - Breast Cancer …, 2024 - Springer
Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways
may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression …
may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression …
Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study
J Chen, Y Zhu, W Wu, Y Xu, W Yang, L Ling… - The …, 2024 - academic.oup.com
Background As a newly identified subtype of HER2-negative tumors associated with a less
favorable prognosis, it remains crucial to evaluate potential prognostic and predictive …
favorable prognosis, it remains crucial to evaluate potential prognostic and predictive …
Potential Use of Extracellular Vesicles for the HER2 Status Assessment in Breast Cancer Patients
S Moon, SI Kim, S Lee, H Lee, Y Kim… - Genes …, 2024 - Wiley Online Library
Human epithelial growth factor receptor 2 (HER2)‐targeted therapies are effective in
patients with HER2‐positive breast cancer. Recent advances have shown that HER2 …
patients with HER2‐positive breast cancer. Recent advances have shown that HER2 …
Development and Validation of a HER2-Low Focused IHC Scoring System with High Inter-Observer Concordance The Australian HER2-low Breast Cancer …
G Farshid, J Armes, B Dessauvagie, A Gilhotra… - Modern Pathology, 2024 - Elsevier
Abstract The DESTINY Breast-04 Trial (DB-04) revealed survival advantages of
Trastuzumab Deruxtecan for women with metastatic HER2-low breast cancer (1+ or 2+ IHC …
Trastuzumab Deruxtecan for women with metastatic HER2-low breast cancer (1+ or 2+ IHC …